|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
143,520,000 |
Market
Cap: |
63.51(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.4425 - $0.4425 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
1,431,765 |
4,794,057 |
4,794,057 |
4,794,057 |
Total Buy Value |
$20,571,167 |
$89,496,413 |
$89,496,413 |
$89,496,413 |
Total People Bought |
1 |
1 |
1 |
1 |
Total Buy Transactions |
2 |
6 |
6 |
6 |
Total Shares Sold |
0 |
6,161,499 |
6,722,029 |
6,722,029 |
Total Sell Value |
$0 |
$121,266,413 |
$128,353,600 |
$128,353,600 |
Total People Sold |
0 |
6 |
7 |
7 |
Total Sell Transactions |
0 |
24 |
32 |
32 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gross Phillip |
10% Owner |
|
2024-04-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
5,156,299 |
|
- |
|
Cormorant Global Healthcare Master Fund, Lp |
|
|
2024-04-18 |
4 |
B |
$17.62 |
$10,489,446 |
I/I |
581,765 |
7,475,000 |
0.01 |
- |
|
Paggiarino Dario A. |
Chief Medical Officer |
|
2024-03-30 |
4 |
D |
$20.67 |
$528,036 |
D/D |
(25,546) |
67,080 |
|
- |
|
Paggiarino Dario A. |
Chief Medical Officer |
|
2024-03-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
50,404 |
92,626 |
|
- |
|
Duker Jay S. |
President and CEO |
|
2024-02-27 |
4 |
GA |
$0.00 |
$0 |
I/I |
2,500 |
22,500 |
|
- |
|
Duker Jay S. |
President and CEO |
|
2024-02-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
2,500 |
29,420 |
|
- |
|
Duker Jay S. |
President and CEO |
|
2024-02-20 |
4 |
GA |
$0.00 |
$0 |
I/I |
20,000 |
20,000 |
|
- |
|
Duker Jay S. |
President and CEO |
|
2024-02-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
20,000 |
31,920 |
|
- |
|
Lurker Nancy |
Executive Vice Chair |
|
2024-02-13 |
4 |
GA |
$0.00 |
$0 |
I/I |
74,681 |
126,889 |
|
- |
|
Lurker Nancy |
Executive Vice Chair |
|
2024-02-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
74,681 |
83,351 |
|
- |
|
Lurker Nancy |
Executive Vice Chair |
|
2024-02-09 |
4 |
D |
$28.80 |
$430,358 |
D/D |
(14,943) |
158,032 |
|
- |
|
Lurker Nancy |
Executive Vice Chair |
|
2024-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,534 |
172,975 |
|
- |
|
Paggiarino Dario A. |
Chief Medical Officer |
|
2024-02-09 |
4 |
D |
$28.80 |
$146,390 |
D/D |
(5,083) |
42,222 |
|
- |
|
Paggiarino Dario A. |
Chief Medical Officer |
|
2024-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,800 |
47,305 |
|
- |
|
Elston George |
Chief Financial Officer |
|
2024-02-09 |
4 |
D |
$28.80 |
$91,930 |
D/D |
(3,192) |
43,607 |
|
- |
|
Elston George |
Chief Financial Officer |
|
2024-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,800 |
46,799 |
|
- |
|
Duker Jay S. |
President and CEO |
|
2024-02-09 |
4 |
D |
$28.80 |
$101,750 |
D/D |
(3,533) |
51,920 |
|
- |
|
Duker Jay S. |
President and CEO |
|
2024-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,967 |
55,453 |
|
- |
|
Jones David Scott |
SVP & Chief Commercial Officer |
|
2024-02-09 |
4 |
D |
$28.80 |
$105,293 |
D/D |
(3,656) |
44,916 |
|
- |
|
Jones David Scott |
SVP & Chief Commercial Officer |
|
2024-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,967 |
48,572 |
|
- |
|
Jones David Scott |
SVP & Chief Commercial Officer |
|
2024-02-02 |
4 |
S |
$28.49 |
$5,954 |
D/D |
(209) |
37,962 |
|
- |
|
Jones David Scott |
SVP & Chief Commercial Officer |
|
2024-02-02 |
4 |
OE |
$11.47 |
$2,397 |
D/D |
209 |
38,171 |
|
- |
|
Paggiarino Dario A. |
Chief Medical Officer |
|
2024-01-26 |
4 |
S |
$25.41 |
$1,265,539 |
D/D |
(49,325) |
36,505 |
|
- |
|
Paggiarino Dario A. |
Chief Medical Officer |
|
2024-01-26 |
4 |
OE |
$12.90 |
$644,047 |
D/D |
49,325 |
85,830 |
|
- |
|
Jones David Scott |
SVP & Chief Commercial Officer |
|
2024-01-26 |
4 |
S |
$25.27 |
$660,370 |
D/D |
(26,017) |
37,962 |
|
- |
|
101 Records found
|
|
Page 1 of 5 |
|
|